CHU Henri Mondor — Clinical Trial Site

10 Registered trials

5 Currently recruiting

Organisation

CHU Henri Mondor

Location

Creteil, France

Identifier

ORL-000001266

Address

1 Rue Gustave Eiffel, Maladies Infectieuses & U2TI, 94000, France

Departments

Hématologie
Maladies Infectieuses & U2TI
Neurology
ONCOLOGIE
Oncologie medicale
ONCOLOGY
Radiotherapy
Service d'immunologie clinique et maladies infectieuses
Service d'Oncologie Médicale - CLIPP
Urologie

Clinical trials at this site (10)

Search interface

CANDIDATE THERAPIES IN COMBINATION OR SEQUENTIALLY WITH TYROSINE KINASE INHIBITORS IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) P… Recruiting

2024-516328-32-00 CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) 4 2024-09-16
Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in … Recruiting

2024-516807-17-00 Relapsing/Refractory ALK+ Anaplastic Large cell Lymphom 4 2019-01-02
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatel… Recruiting

2024-510772-20-00 Rectal cancer locally advanced with microsatellite unst 4 2025-02-06
A clinical study of sacituzumab tirumotecan (sac-TMT) in people with bladder cancer (MK-2870-027) Recruiting

2024-514983-23-01 Intermediate-risk Non-muscle Invasive Bladder Cancer 9 2024-12-16
Partial oral antibiotic treatment for bacterial brain abscess: An open-label randomised non-inferiority trial (ORAL) Recruiting

2023-505483-11-00 Brain abscess 6 2021-05-02
A phase 1/2a multicenter trial to evaluate the safety and immunogenicity of the CD40.Pan.CoV vaccine, adjuvanted or not, as a booster in adu… Ended

2024-516767-92-01 Health Participants 1 2025-06-17
PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed… Ended

2023-505972-32-00 locally advanced anal squamous cell carcinoma 5 2024-02-26
Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients Ended

2024-515171-35-00 Prostatic adenocarnicoma with high risk of recurrence 5 2011-07-06
A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib… Ended

2024-516672-16-00 Multiple Sclerosis 5 2024-02-02
SENS-401 to Prevent the Ototoxicity induced by Cisplatin in Adult Subjects with a Neoplastic Disease Ended

2024-511713-38-00 Cisplatine induced hearing loss 4 2022-12-30